share_log

iBio Inc | 8-K: Current report

iBio Inc | 8-K: Current report

iBio Inc | 8-K:重大事件
美股SEC公告 ·  07/09 16:06

Moomoo AI 已提取核心訊息

On July 2, 2024, iBio Inc, a biotechnology company incorporated in Delaware, filed a Form 8-K with the SEC to report the approval of new forms of award agreements by the company's Board. These agreements are designed for the grant of stock options and restricted stock units to directors, executive officers, employees, and consultants under iBio's 2023 Plan. The agreements include various terms and vesting criteria, with provisions detailing the exercise price payment methods and the treatment of awards upon termination of service for different reasons. Additionally, iBio Inc adopted an updated Code of Business Conduct and Ethics applicable to all directors, officers, and employees, replacing the previous code to better reflect the company's operations and mitigate risk. The full text of the Award Agreements and the updated Code are attached to the report as exhibits.
On July 2, 2024, iBio Inc, a biotechnology company incorporated in Delaware, filed a Form 8-K with the SEC to report the approval of new forms of award agreements by the company's Board. These agreements are designed for the grant of stock options and restricted stock units to directors, executive officers, employees, and consultants under iBio's 2023 Plan. The agreements include various terms and vesting criteria, with provisions detailing the exercise price payment methods and the treatment of awards upon termination of service for different reasons. Additionally, iBio Inc adopted an updated Code of Business Conduct and Ethics applicable to all directors, officers, and employees, replacing the previous code to better reflect the company's operations and mitigate risk. The full text of the Award Agreements and the updated Code are attached to the report as exhibits.
2024年7月2日,註冊於特拉華州的生物技術公司ibio inc向美國證券交易委員會提交了一份8-k表格,以報告公司董事會批准了新的獎勵協議形式。這些協議旨在授予ibio 2023計劃下的董事、高管、員工和顧問股票期權和受限制的股票單位。這些協議包括各種條款和歸屬條件,規定行權價格支付方法以及因不同原因終止服務時獎勵的處理方式。此外,ibio inc還採用了更新後的業務行爲準則和倫理準則,適用於所有董事、高管和員工,以取代以前的準則,以更好地反映公司的經營和降低風險。獎勵協議和更新的準則的全文已作爲展品附在報告中。
2024年7月2日,註冊於特拉華州的生物技術公司ibio inc向美國證券交易委員會提交了一份8-k表格,以報告公司董事會批准了新的獎勵協議形式。這些協議旨在授予ibio 2023計劃下的董事、高管、員工和顧問股票期權和受限制的股票單位。這些協議包括各種條款和歸屬條件,規定行權價格支付方法以及因不同原因終止服務時獎勵的處理方式。此外,ibio inc還採用了更新後的業務行爲準則和倫理準則,適用於所有董事、高管和員工,以取代以前的準則,以更好地反映公司的經營和降低風險。獎勵協議和更新的準則的全文已作爲展品附在報告中。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息